Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5B | Q9UGL1 | 14/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | KDM5A | P29375 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.31 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.30 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31676967 | 0.86 | KDM5B (0.47) | KDM5BTSHRKDM5AALDH1A1TLR9 | |
| SCHEMBL20074336 | 0.86 | KDM5B (0.47) | KDM5BTSHRKDM5AALDH1A1TLR9 | |
| SCHEMBL20074331 | 0.85 | KDM5B (0.43) | KDM5BTSHRTDP1ALDH1A1SIRT5 | |
| SCHEMBL20074277 | 0.84 | KDM5B (0.42) | KDM5BTSHRKDM5ATDP1ALDH1A1 | |
| SCHEMBL20074140 | 0.83 | KDM5B (0.52) | KDM5BTSHRTLR9TLR8TLR7 | |
| SCHEMBL20074119 | 0.83 | KDM5B (0.46) | KDM5BTSHRKDM5AALDH1A1SIRT5 | |
| SCHEMBL21721735 | 0.83 | KDM5B (0.47) | KDM5BTSHRKDM5ATLR9TLR8 | |
| SCHEMBL20074320 | 0.83 | KDM5B (0.46) | KDM5BTSHRTLR9TLR8TLR7 | |
| SCHEMBL21721765 | 0.82 | KDM5B (0.53) | KDM5BTSHRTLR9TLR8TLR7 | |
| SCHEMBL31677001 | 0.82 | KDM5B (0.53) | KDM5BTSHRTLR9TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3525785-B1 | KDM5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-08-27 | — | — | EP | claimed |
| US-10975084-B2 | KDM5 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20200048258-A1 | KDM5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-02-13 | — | — | US | disclosed |
| WO-2018071283-A1 | KDM5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048258-A1 | KDM5 INHIBITORS | KDM5A, KDM5B, KDM5C | KDM5B 2/4885TSHR 4342/4885KDM5A 1/4885 |
| US-10975084-B2 | KDM5 inhibitors | KDM5A, KDM5B, KDM5C | KDM5B 2/4885TSHR 4342/4885KDM5A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.